
Pharmaceutical major Eli Lilly and Company (LLY) is scheduled to release its third-quarter results on November 2. While its earnings are expected to decline year-over-year, its revenue will likely improve.
In this piece, I have discussed why waiting for an opportune entry point in the stock could be wise.